Corneal in vivo confocal microscopy to detect belantamab mafodotin-induced ocular toxicity early and adjust the dose accordingly: a case report
Abstract Background New targeted antibody–drug conjugates (ADCs) against multiple myeloma are known to induce adverse effects that may lead to treatment discontinuation. Preclinical studies reported early severe ocular damage related to the use of belantamab mafodotin (belamaf), including ocular sur...
Main Authors: | Kevin Marquant, Anne Quinquenel, Carl Arndt, Alexandre Denoyer |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-10-01
|
Series: | Journal of Hematology & Oncology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13045-021-01172-5 |
Similar Items
-
Clinical features and in vivo confocal microscopy assessment in 12 patients with ocular cicatricial pemphigoid
by: Qin Long, et al.
Published: (2016-05-01) -
Advances in the application of confocal microscopy to keratopathy
by: Qiao Zheng, et al.
Published: (2019-09-01) -
Confocal microscopy features in chronic corneal edema
by: Yun-Juan Su, et al.
Published: (2019-12-01) -
Belantamab Mafodotin: From Clinical Trials Data to Real-Life Experiences
by: Sonia Morè, et al.
Published: (2023-05-01) -
Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety
by: Offidani M, et al.
Published: (2021-06-01)